Navigation Links
Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
Date:4/13/2009

t a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic and therapeutic strategy for many diseases.

About Rosetta Genomics

Rosetta Genomics is a leading molecular diagnostics company committed to develop and commercialize products based on microRNAs for targeted therapy and preventive medicine. Rosetta developed a unique methodology to find microRNAs in body fluids and other clinical samples, and discovered in the past few years hundreds of novel microRNAs that can be used as important biomarkers and drug targets. Rosetta performs its commercial molecular diagnostics tests at Rosetta Laboratories in Philadelphia. Building on its strong intellectual property position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development of novel molecular diagnostics products.

About Prometheus

Prometheus Laboratories Inc. is a specialty pharmaceutical and diagnostic company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and intends to apply these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary, high-value diagnostic testing services. By integrating pharmaceutical products and diagnostic testing services, Prometheus believes it can address the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego.

Rosetta Forward-Looking Statements

Various statement
'/>"/>

SOURCE Prometheus Laboratories Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
2. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
3. Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests
4. Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics miRview(TM) Squamous Assay
5. MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
6. Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
7. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
8. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
9. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
10. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
11. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 2014  Sprout Pharmaceuticals today announced positive preliminary results from ... with flibanserin up to 200 mg at bedtime had no ... the 20 th Annual Fall Scientific Meeting of the ... in Miami . The Phase ... Response Letter and the Formal Dispute Resolution that was filed ...
(Date:11/22/2014)... 21 de noviembre de 2014  BioClinica®, Inc., ... externalizados y tecnologías eClinical, ha indicado un aumento ... inteligente, para el seguimiento basado en el riesgo ... el concepto del seguimiento basado en el riesgo ... visitas de seguimiento o cambio de los métodos ...
(Date:11/22/2014)... , Nov. 21, 2014 MEDITE Group acquired ... nine months and the 3 rd quarter sales ended ... income was $448,000 for the nine months ended September 2014 ... "Even though our 3 rd quarter is usually a ... extends from July into September for many countries worldwide, we ...
Breaking Medicine Technology:Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3
... ("Volition" or the "Company"), a life sciences company focused on ... shareholders from Cameron Reynolds, CEO: Dear Shareholders, ... growing and the fact that we have been reaching our ... and look forward to future goals that will continue to ...
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ... and infectious diseases, announced today that VGX-3100, its investigational ... by human papillomavirus, was highlighted by Fierce Vaccines ... (see VGX-3100 – Cervical cancer). Inovio is currently ...
Cached Medicine Technology:VolitionRX Limited Issues Update Letter to Shareholders 2VolitionRX Limited Issues Update Letter to Shareholders 3VolitionRX Limited Issues Update Letter to Shareholders 4VolitionRX Limited Issues Update Letter to Shareholders 5Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling 2Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling 3Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling 4Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling 5Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling 6
(Date:11/24/2014)... The Mesothelioma Applied Research Foundation ... on Malignant Mesothelioma from March 2nd through March 4th ... take place on the campus of the National Institutes ... dinner and an awards ceremony, will be held at ... range of topics about pleural and peritoneal mesothelioma, treatments, ...
(Date:11/24/2014)... November 24, 2014 A new ... London's pre-eminent pain-relief service and massage therapy provider, ... Massage (ESM). This newest sports massage ... key difference between traditional sports massage and ESM ... the body's very own "reset button,” and ESM ...
(Date:11/24/2014)... SWAccessControl.com has recently released a new collection of ... company is a leading online supplier in the international market. ... at discounted prices, up to 30% off. , “We are ... time, all of our items are offered at low rates. ... I have confidence in our fresh assortment. You will have ...
(Date:11/24/2014)... CO, and Philadelphia, PA (PRWEB) November 24, 2014 ... provider of care coordination and disease management services ... has chosen to implement Essette’s Medical Management software ... new Essette SaaS platform in a program to ... Essette suite includes Population Health Management, Care Management, ...
(Date:11/23/2014)... Dallas, TX (PRWEB) November 24, 2014 ... Trials Review, H2, 2014" provides data on the ... information and data relating to the clinical trials ... trial numbers and their recruitment status as per ... The databook offers a preliminary coverage of disease ...
Breaking Medicine News(10 mins):Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 2Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 3Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 2Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 3Health News:SWAccessControl.com Is Happy To Release New Range Of Magnetic Locks 2Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4
... March 31 A new study in The ... benefits for nurses and patients when continuous vigilance monitoring ... were definitive," stated Dr. Patrick Sullivan, President and CEO ... an early alert to RNs about potential patient deterioration ...
... , - "Thinking Outside ... , Elsevier, a leading ... in the Elsevier Article 2.0 Contest (, http://www.article20.elsevier.com ... useful solutions for rendering journal articles on the,web. ...
... employers across North Carolina , ... Englewood, CO (Vocus) ... life science careers and information, unveiled the seventh edition of the ... , ,This regional campaign is a promotional effort highlighting biotechnological, pharmaceutical ...
... $25 Monthly Fee for Copayments , ... Mineola, NY ... the nation,s lowest cost provider of merchant services, is pleased to ... doctors, dentists, chiropractors, podiatrists and other health care professionals., , ,The ...
... Government Facilities Offer Greater Work-Life Balance , ... Alpharetta, ... recent LocumTenens.com physician survey, only 11% had not worked ... of respondents, most (82%) said they were interested in trying government ...
... China, March 31 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, ... (Nasdaq: CSKI ), a,leading fully integrated ... of China ("PRC"), today announced that it has,cancelled ... a.m. EDT,on March 31, 2009. The Company will ...
Cached Medicine News:Health News:Continuous Vigilance Monitoring Technology Benefits Nurses & Patients 2Health News:Three Prize Winners Awarded in Elsevier's Article 2.0 Contest 2Health News:Three Prize Winners Awarded in Elsevier's Article 2.0 Contest 3Health News:BioSpace Launches the 2009 Bio NC™ Hotbed Campaign 2Health News:EnablePay Announces Special Payments Processing Program for Doctors, Dentists And Other Health Care Professionals 2Health News:Physician Survey Highlights Advantages of Government Locum Tenens Jobs 2Health News:Physician Survey Highlights Advantages of Government Locum Tenens Jobs 3Health News:China Sky One Medical, Inc. Delays Fourth Quarter and Full Year 2008 Earnings Conference Call 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: